FNYS
ATXS

First New York Securities’s Astria Therapeutics ATXS Stock Holding History

First New York Securities’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-13
Closed -$4.62K – 97
2016
Q3 		$4.62K Hold
13
– – ﹤0.01% 212
2016
Q2 		$2.77K Buy
+13
New +$3.92K ﹤0.01% 181

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First New York Securities's ATXS Position: Q4 2016 in Review

First New York Securities sold out of Astria Therapeutics (ATXS) in Q4 2016, closing a stake of 13 shares — an estimated $4.62K sold.

First New York Securities first reported a position in ATXS in Q2 2016 and held it in 2 quarters. The position peaked at $4.62K in Q3 2016. 26 funds tracked by Wall St. Rank hold ATXS as of Q4 2016.

  • First New York Securities reported no remaining Astria Therapeutics position as of Q4 2016 after selling out during the quarter.
  • First New York Securities sold 13 Astria Therapeutics shares in Q4 2016, an estimated $4.62K.
  • First New York Securities first reported a position in Astria Therapeutics in Q2 2016 and held it in 2 quarters.
  • First New York Securities's Astria Therapeutics position peaked at $4.62K in Q3 2016.
  • 26 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2016.

Based on First New York Securities's 13F filing for Q4 2016, filed 7 Feb 2017.